The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. Seattle, WA 98109, 75 Kneeland Street Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology. Shape Therapeutics is a development-stage biotechnology company. Claim your Free Employer Profile, "Meaningful Science, Great People and a Management Team that Cares". Shape Therapeutics is . Looking for a particular Shape Therapeutics, Inc. employee's phone or email? April 20, 2021 08:00 ET from Harvard Law School. Shape Therapeutics Inc. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. Its gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. ", I feel this real connection to the patients were having an impact on. Engineering best-in-class. Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). Explore {Shape Therapeutics's key management people. Shape Life! With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . Get started with your Free Employer Profile, Work Here? Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Lorem ipsum dolor sit, amet consectetur adipisicing elit. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Type Private Status Active Founded 2018 HQ Great team culture. Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 10% of PTC Therapeutics management is Hispanic or Latino. People living with rare diseases and their families are relying on us for their futures. Investors & Media . Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. Discover current leadership team members including founders, CEO, other executives and board directors. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. As Doug noted, our full year net product revenue was $843.8 million . Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. What is health insurance like at Shape Therapeutics? Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. Meet members of our executive team at StrideBio. Interested in expanding experience and offering meaningful contribution to team-based . 219 Terry Avenue North I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. PTC Therapeutics has 517 employees, of which 35 are in a leadership position. As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. All rights reserved. Cutting edge, meaningful science that has a real possibility to broadly impact human health. At this time, all participants are in a listen-only mode . 56% of the management team is White. Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. John C. Martin, Ph.D., was elected to our Board in January 2020. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Working at Shape has been great! We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. A free inside look at company reviews and salaries posted anonymously by employees. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). Interested in researching Shape Therapeutics? | Source: And I thought, imagine how Ill feel if we can reach more kids. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack Powered by Madgex Job Board Software. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. Shape Life! See what employees say it's like to work at Shape Therapeutics. Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. Enter employee name to find & verify emails, phones, social links, etc. We have to be creative; we need to transform the paradigm. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Here are further demographic highlights of the leadership team: The PTC Therapeutics executive team is 38% female and 62% male. Shape Therapeutics's is . Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Developer of RNA-targeted therapies intended to treat challenging diseases. About. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. The net loss for the full . SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Shape Life! Its very rewarding. Shape Therapeutics's key executives include David Huss and 11 others. Shape Life! Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. Last Funding Type Series B. Sign up for a free account. Operator. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. Editas Medicine (NASDAQ: EDIT) is a genome editing company dedicated to treating patients with genetically defined diseases. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. We [] Mastery of our AI-driven platform allows us to create programmable RNA medicines across diseases and modalities. At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. Personalize which data points you want to see and create visualizations instantly. Shape Therapeutics, Inc. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital. focus on diversity and equityRead More. Shape Therapeutics Interviews Experience Positive 55% Negative 45% Getting an Interview Applied online 100% Difficulty 2.7 Average Hard Average Easy Sep 1, 2022 Research Associate/ Sr. RA/ Assoc. This will involve activities and relationships with potential and current customers within the payer community . Rznomics was founded in 2017 and is based in Yongin-si, South Korea. Win whats next. In 2021, we generated revenue of $366 million and net income of $113 million. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. This is a profile preview from the PitchBook Platform. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer Get contact details including emails and phone numbers David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice Lorem ipsum dolor sit amet consectetur adipisicing elit. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). Shape Therapeutics, Inc. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. No credit card required. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Up to 5 We have this culture of innovating. Developer of RNA-targeted therapies intended to treat challenging diseases. Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. Interested in what they do or partnership? Shape Therapeutics, Inc. employs 14 employees. The company closed a series B financing led by . ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. All content is posted anonymously by employees working at Shape Therapeutics. Headquarters Location 219 Terry Ave N Suite 100 We know why we get up every day and work as hard as we do. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. Operating Status Active. Shape Therapeutics's Vice President, Head of Research is David Huss. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer.